Research report: Cost-Utility Analysis of Bortezomib, Thalidomide and Lenalidomide for Relapsed/Refractory Multiple Myeloma Treatment
Home >
News
>
Publications
>
Documents > Research Reports > Research report: Cost-Utility Analysis of Bortezomib, Thalidomide and Lenalidomide for Relapsed/Refractory Multiple Myeloma Treatment